RxDoctor Payments Data

Juliet Richards

Family · Gulfport, MSNPI 1053554808

Payments from drug & device makers

$2,710in general payments, 2019–2025

Across 134 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$546
  • Boehringer Ingelheim$511
  • Lilly USA, LLC$503
  • Novo Nordisk$182
  • AbbVie$160
  • Paratek Pharmaceuticals, Inc.$140
  • plus $668 from 13 others

What the payments were for

  • Food & beverage$2,710100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,710 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$12,117
Medicare patients
55
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin47$64,412
OzempicSemaglutide19$19,116
SynjardyEmpagliflozin/Metformin Hcl18$12,589
TrulicityDulaglutide11$11,166
Tresiba Flextouch U-100Insulin Degludec15$3,413
Duloxetine Hcl31$1,322
Rosuvastatin Calcium87$1,170
Albuterol Sulfate HfaAlbuterol Sulfate21$676
Fluticasone Propionate41$674
Omega-3 Acid Ethyl Esters12$669
Omeprazole61$583
Lisinopril98$486
Atorvastatin Calcium87$452
Metformin Hcl100$445
Tizanidine Hcl48$425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy$511$77,00165 claims
Novo NordiskOzempic$182$19,11619 claims
Lilly USA, LLCTrulicity$503$11,16611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.

Other family in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →